Cancer Treatment Could Face Landmark Moment with Promising Vaccine

An experimental drug that uses messenger RNA to deliver a vaccine customized to a patient's tumors effectively prevented skin cancer recurrence in a large-scale clinical trial, according to new results announced by drugmakers Wednesday.

Researchers have explored the use of mRNA drugs — the same technology behind the leading coronavirus vaccines that helped end the pandemic — to treat cancer for years, but this one is the first to clear a Phase 3 trial, according to Moderna and Merck.

That opens the door for the Food and Drug Administration (FDA) to potentially approve the first mRNA-based cancer treatment, in what would be a landmark moment for the fast-emerging field.

Please select this link to read the complete article from The Washington Post.